Sinphar Pharmaceutical Co Ltd - Asset Resilience Ratio
Sinphar Pharmaceutical Co Ltd (1734) has an Asset Resilience Ratio of 2.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Sinphar Pharmaceutical Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Sinphar Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 1734 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sinphar Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Sinphar Pharmaceutical Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$130.49 Million | 2.12% |
| Total Liquid Assets | NT$130.49 Million | 2.12% |
Asset Resilience Insights
- Limited Liquidity: Sinphar Pharmaceutical Co Ltd maintains only 2.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sinphar Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sinphar Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Sinphar Pharmaceutical Co Ltd (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Sinphar Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.12% | NT$130.49 Million ≈ $4.11 Million |
NT$6.15 Billion ≈ $193.85 Million |
+0.50pp |
| 2024-12-31 | 1.63% | NT$102.36 Million ≈ $3.23 Million |
NT$6.30 Billion ≈ $198.43 Million |
+1.52pp |
| 2023-12-31 | 0.11% | NT$6.66 Million ≈ $209.83K |
NT$6.25 Billion ≈ $196.94 Million |
0.00pp |
| 2022-12-31 | 0.11% | NT$6.66 Million ≈ $209.83K |
NT$6.19 Billion ≈ $194.87 Million |
-0.70pp |
| 2021-12-31 | 0.81% | NT$50.10 Million ≈ $1.58 Million |
NT$6.22 Billion ≈ $195.99 Million |
-0.02pp |
| 2020-12-31 | 0.82% | NT$50.43 Million ≈ $1.59 Million |
NT$6.13 Billion ≈ $193.03 Million |
+0.06pp |
| 2019-12-31 | 0.77% | NT$45.41 Million ≈ $1.43 Million |
NT$5.92 Billion ≈ $186.40 Million |
+0.48pp |
| 2018-12-31 | 0.28% | NT$16.62 Million ≈ $523.50K |
NT$5.88 Billion ≈ $185.19 Million |
-1.28pp |
| 2017-12-31 | 1.56% | NT$94.31 Million ≈ $2.97 Million |
NT$6.04 Billion ≈ $190.39 Million |
+0.83pp |
| 2016-12-31 | 0.73% | NT$45.21 Million ≈ $1.42 Million |
NT$6.21 Billion ≈ $195.54 Million |
-0.94pp |
| 2015-12-31 | 1.67% | NT$106.53 Million ≈ $3.36 Million |
NT$6.39 Billion ≈ $201.21 Million |
+0.68pp |
| 2014-12-31 | 0.99% | NT$63.70 Million ≈ $2.01 Million |
NT$6.46 Billion ≈ $203.65 Million |
-1.44pp |
| 2013-12-31 | 2.42% | NT$138.06 Million ≈ $4.35 Million |
NT$5.70 Billion ≈ $179.69 Million |
+0.49pp |
| 2012-12-31 | 1.93% | NT$87.42 Million ≈ $2.75 Million |
NT$4.54 Billion ≈ $142.90 Million |
+0.44pp |
| 2011-12-31 | 1.49% | NT$69.04 Million ≈ $2.18 Million |
NT$4.64 Billion ≈ $146.14 Million |
+1.08pp |
| 2010-12-31 | 0.40% | NT$14.99 Million ≈ $472.24K |
NT$3.71 Billion ≈ $116.99 Million |
-1.62pp |
| 2009-12-31 | 2.02% | NT$72.46 Million ≈ $2.28 Million |
NT$3.58 Billion ≈ $112.93 Million |
-10.36pp |
| 2008-12-31 | 12.38% | NT$444.77 Million ≈ $14.01 Million |
NT$3.59 Billion ≈ $113.20 Million |
+11.59pp |
| 2007-12-31 | 0.79% | NT$25.09 Million ≈ $790.54K |
NT$3.16 Billion ≈ $99.70 Million |
-0.35pp |
| 2006-12-31 | 1.14% | NT$31.69 Million ≈ $998.38K |
NT$2.77 Billion ≈ $87.42 Million |
-0.34pp |
| 2005-12-31 | 1.48% | NT$42.03 Million ≈ $1.32 Million |
NT$2.84 Billion ≈ $89.45 Million |
+0.02pp |
| 2004-12-31 | 1.46% | NT$34.23 Million ≈ $1.08 Million |
NT$2.35 Billion ≈ $73.93 Million |
+0.62pp |
| 2003-12-31 | 0.84% | NT$17.37 Million ≈ $547.38K |
NT$2.06 Billion ≈ $64.92 Million |
-- |
About Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more